blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3375792

EP3375792 - DERIVATIVES OF N-DESULFATED GLYCOSAMINOGLYCANS AND USE AS DRUGS [Right-click to bookmark this link]
Former [2018/38]DERIVATIVES OF N-DESULFATED GLUCOSAMINOGLYCANS AND USE AS DRUGS
[2019/35]
StatusNo opposition filed within time limit
Status updated on  20.03.2020
Database last updated on 26.03.2026
FormerThe patent has been granted
Status updated on  12.04.2019
FormerGrant of patent is intended
Status updated on  18.11.2018
FormerRequest for examination was made
Status updated on  17.08.2018
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Novahealth Biosystems LLC
700 E. Main Street
Waunakee, WI 53597 / US
[2018/38]
Inventor(s)01 / NAGGI, Annamaria
Viale Luigi Cadorna 27
20025 Legnano / IT
02 / TORRI, Giangiacomo
Via don Francesco Beniamino della Torre 2
20157 Milano / IT
 [2018/38]
Representative(s)Cohausz & Florack
Patent- & Rechtsanwälte
Partnerschaftsgesellschaft mbB
Bleichstraße 14
40211 Düsseldorf / DE
[2018/38]
Application number, filing date18170785.223.10.2014
[2018/38]
Priority number, dateIT2013LO0000531.10.2013         Original published format: IT LO20130005
[2018/38]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3375792
Date:19.09.2018
Language:EN
[2018/38]
Type: B1 Patent specification 
No.:EP3375792
Date:15.05.2019
Language:EN
[2019/20]
Type: B9 Corrected patent specification 
No.:EP3375792
Date:13.11.2019
[2019/46]
Search report(s)(Supplementary) European search report - dispatched on:EP05.07.2018
ClassificationIPC:C08B37/00, A61K31/726, A61K31/727, A61K31/728, A61K31/737, C08B37/08
[2018/38]
CPC:
C08B37/0075 (EP,KR,US); C08B37/0063 (EP,KR,US); A61K31/726 (EP,KR,US);
A61K31/727 (EP,KR,US); A61K31/728 (EP,KR,US); A61K31/737 (EP,KR,US);
A61P35/00 (EP); A61P35/04 (EP); C08B37/0069 (EP,KR,US);
C08B37/0072 (EP,KR,US); C08B37/0078 (EP,KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/49]
Former [2018/38]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:DERIVATE VON N-DESULFATIERTEN GLYKOSAMINOGLYKANEN UND VERWENDUNG ALS ARZNEIMITTEL[2019/35]
English:DERIVATIVES OF N-DESULFATED GLYCOSAMINOGLYCANS AND USE AS DRUGS[2019/35]
French:DÉRIVÉS DE GLYCOSAMINOGLYCANES N-DÉSULFATÉE ET LEUR UTILISATION COMME MÉDICAMENTS[2018/38]
Former [2018/38]DERIVATE VON N-DESULFATIERTEN GLUCOSAMINOGLYCANEN UND VERWENDUNG ALS ARZNEIMITTEL
Former [2018/38]DERIVATIVES OF N-DESULFATED GLUCOSAMINOGLYCANS AND USE AS DRUGS
Examination procedure04.05.2018Date on which the examining division has become responsible
03.08.2018Examination requested  [2018/38]
19.11.2018Communication of intention to grant the patent
25.03.2019Fee for grant paid
25.03.2019Fee for publishing/printing paid
25.03.2019Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP14798720.0  / EP3063177
Opposition(s)18.02.2020No opposition filed within time limit [2020/17]
Fees paidRenewal fee
04.05.2018Renewal fee patent year 03
04.05.2018Renewal fee patent year 04
29.10.2018Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU23.10.2014
AL15.05.2019
CZ15.05.2019
EE15.05.2019
HR15.05.2019
LT15.05.2019
LV15.05.2019
MC15.05.2019
MK15.05.2019
MT15.05.2019
RO15.05.2019
RS15.05.2019
SI15.05.2019
SK15.05.2019
SM15.05.2019
BG15.08.2019
NO15.08.2019
IS15.09.2019
[2022/32]
Former [2021/48]HU23.10.2014
AL15.05.2019
CZ15.05.2019
EE15.05.2019
HR15.05.2019
LT15.05.2019
LV15.05.2019
MC15.05.2019
MT15.05.2019
RO15.05.2019
RS15.05.2019
SI15.05.2019
SK15.05.2019
SM15.05.2019
BG15.08.2019
NO15.08.2019
IS15.09.2019
Former [2021/34]HU23.10.2014
AL15.05.2019
CZ15.05.2019
EE15.05.2019
HR15.05.2019
LT15.05.2019
LV15.05.2019
MC15.05.2019
MT15.05.2019
RO15.05.2019
RS15.05.2019
SK15.05.2019
SM15.05.2019
BG15.08.2019
NO15.08.2019
IS15.09.2019
Former [2021/32]HU23.10.2014
AL15.05.2019
CZ15.05.2019
EE15.05.2019
HR15.05.2019
LT15.05.2019
LV15.05.2019
MC15.05.2019
RO15.05.2019
RS15.05.2019
SK15.05.2019
SM15.05.2019
BG15.08.2019
NO15.08.2019
IS15.09.2019
Former [2021/31]AL15.05.2019
CZ15.05.2019
EE15.05.2019
HR15.05.2019
LT15.05.2019
LV15.05.2019
MC15.05.2019
RO15.05.2019
RS15.05.2019
SK15.05.2019
SM15.05.2019
BG15.08.2019
NO15.08.2019
IS15.09.2019
Former [2021/20]AL15.05.2019
CZ15.05.2019
EE15.05.2019
HR15.05.2019
LT15.05.2019
LV15.05.2019
MC15.05.2019
RO15.05.2019
RS15.05.2019
SK15.05.2019
SM15.05.2019
BG15.08.2019
NO15.08.2019
Former [2020/29]AL15.05.2019
CZ15.05.2019
EE15.05.2019
HR15.05.2019
LT15.05.2019
LV15.05.2019
MC15.05.2019
RS15.05.2019
SK15.05.2019
SM15.05.2019
BG15.08.2019
NO15.08.2019
Former [2020/14]AL15.05.2019
CZ15.05.2019
EE15.05.2019
HR15.05.2019
LT15.05.2019
LV15.05.2019
RS15.05.2019
SK15.05.2019
SM15.05.2019
BG15.08.2019
NO15.08.2019
Former [2020/11]AL15.05.2019
CZ15.05.2019
EE15.05.2019
HR15.05.2019
LT15.05.2019
LV15.05.2019
RS15.05.2019
SK15.05.2019
BG15.08.2019
NO15.08.2019
Former [2020/10]AL15.05.2019
CZ15.05.2019
HR15.05.2019
LT15.05.2019
LV15.05.2019
RS15.05.2019
BG15.08.2019
NO15.08.2019
Former [2019/52]AL15.05.2019
HR15.05.2019
LT15.05.2019
LV15.05.2019
RS15.05.2019
BG15.08.2019
NO15.08.2019
Former [2019/50]AL15.05.2019
HR15.05.2019
LT15.05.2019
LV15.05.2019
RS15.05.2019
NO15.08.2019
Former [2019/47]LT15.05.2019
NO15.08.2019
Documents cited:Search[A] WO03022291  (SIGMA TAU IND FARMACEUTI et al.) [A] 1-15 * page 25; example 1; claims 9,17 *
 [A]   A. NAGGI: "Modulation of the Heparanase-inhibiting Activity of Heparin through Selective Desulfation, Graded N-Acetylation, and Glycol Splitting", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 280, no. 13, 17 November 2004 (2004-11-17), pages 12103 - 12113, XP055034072, ISSN: 0021-9258, DOI: 10.1074/jbc.M414217200 [A] 1-15 * page 12104, column 2, paragraph 4 - page 12105, column 1, paragraph 4; figure 4 *

DOI:   http://dx.doi.org/10.1074/jbc.M414217200
 [A]   CASU B ET AL: "Undersulfated and Glycol-Split Heparins Endowed with Antiangiogenic Activity", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 47, 8 January 2004 (2004-01-08), pages 838 - 848, XP002492012, ISSN: 0022-2623, [retrieved on 20040108], DOI: 10.1021/JM030893G [A] 1-15 * page 864, column 1, paragraph 2 - page 864, column 2, paragraph 2; figure 1 *

DOI:   http://dx.doi.org/10.1021/JM030893G
 [A]   PISANO C ET AL: "Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist", GLYCOBIOLOGY,, vol. 15, no. 2, 1 February 2005 (2005-02-01), pages 1C - 6C, XP008116008, DOI: 10.1093/GLYCOB/CWI007 [A] 1-15 * figure 1a *

DOI:   http://dx.doi.org/10.1093/glycob/cwi007
 [A]   FRANSSON L A ET AL: "Relationship between anticoagulant activity of heparin and susceptibility to periodate oxidation", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 97, no. 1, 1 January 1979 (1979-01-01), pages 119 - 123, XP025604547, ISSN: 0014-5793, [retrieved on 19790101], DOI: 10.1016/0014-5793(79)80065-4 [A] 1-15 * page 120, column 1, paragraph 5 - page 122, column 1, paragraph 3 *

DOI:   http://dx.doi.org/10.1016/0014-5793(79)80065-4
 [A]   CASU BENITO ET AL: "Non-anticoagulant heparins and inhibition of cancer", PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS, KARGER, CH, vol. 36, no. 3-4, 1 January 2008 (2008-01-01), pages 195 - 203, XP009146824, ISSN: 1424-8832 [A] 1-15 * page 196, column 2, paragraph 2 - page 199, column 2, paragraph 1; figures 2,3 *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.